Adriamycin does not damage podocytes of zebrafish larvae

Maximilian Schindler1, Antje Blumenthal1, Marcus Johannes Moeller2

  • 1Department of Anatomy and Cell Biology, University Medicine Greifswald, Greifswald, Germany.

Plos One
|November 13, 2020
PubMed

Insights

Adriamycin does not induce kidney damage in zebrafish larvae, hindering efforts to screen for focal segmental glomerulosclerosis (FSGS) drugs. Further research is needed to establish a reliable FSGS model in zebrafish for drug discovery.

Area of Science:

  • Nephrology
  • Developmental Biology
  • Toxicology

Background:

  • Podocytes are crucial for kidney filtration; injury leads to diseases like focal segmental glomerulosclerosis (FSGS).
  • Effective treatments for FSGS are lacking, necessitating drug screening.
  • Zebrafish larvae offer a promising model for kidney research due to their homology and rapid development.

Purpose of the Study:

  • To establish a zebrafish model for inducing FSGS-like kidney injury using adriamycin.
  • To evaluate adriamycin's efficacy in causing podocyte damage and glomerular dysfunction in zebrafish larvae.

Main Methods:

  • Zebrafish larvae were exposed to varying concentrations of adriamycin.
  • Kidney integrity was assessed using histology, filtration assays, 2-photon microscopy, RT-(q)PCR, and transmission electron microscopy.

Main Results:

  • Adriamycin treatment did not cause glomerular injury or filtration barrier defects in zebrafish larvae.
  • Histological and imaging analyses confirmed intact podocytes and filtration barriers post-treatment.

Conclusions:

  • Adriamycin is ineffective in inducing podocyte damage or FSGS-like phenotypes in zebrafish larvae.
  • Developing a reliable method to induce FSGS in zebrafish is essential for future drug screening and discovery.

Related Concept Videos